Hologic, Inc. (HOLX) Position Trimmed by American International Group Inc.

American International Group Inc. trimmed its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 11.5% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 99,467 shares of the medical equipment provider’s stock after selling 12,883 shares during the period. American International Group Inc.’s holdings in Hologic were worth $3,649,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently modified their holdings of HOLX. Hall Laurie J Trustee increased its holdings in Hologic by 10.2% during the second quarter. Hall Laurie J Trustee now owns 2,425 shares of the medical equipment provider’s stock worth $110,000 after buying an additional 225 shares during the last quarter. Commonwealth Bank of Australia increased its holdings in shares of Hologic by 31.0% in the second quarter. Commonwealth Bank of Australia now owns 2,533 shares of the medical equipment provider’s stock valued at $114,000 after purchasing an additional 600 shares during the last quarter. MPS Loria Financial Planners LLC acquired a new position in shares of Hologic in the second quarter valued at $191,000. National Asset Management Inc. acquired a new position in shares of Hologic in the second quarter valued at $203,000. Finally, Cambridge Investment Research Advisors Inc. acquired a new position in shares of Hologic in the second quarter valued at $213,000. Institutional investors and hedge funds own 98.09% of the company’s stock.

In related news, VP Karleen Marie Oberton sold 1,023 shares of the company’s stock in a transaction dated Monday, November 20th. The shares were sold at an average price of $39.84, for a total value of $40,756.32. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Lawrence M. Levy sold 7,138 shares of the company’s stock in a transaction dated Monday, October 9th. The shares were sold at an average price of $37.38, for a total transaction of $266,818.44. The disclosure for this sale can be found here. Insiders sold 28,833 shares of company stock worth $1,107,270 over the last 90 days. 0.79% of the stock is currently owned by corporate insiders.

Hologic, Inc. (NASDAQ:HOLX) opened at $41.44 on Thursday. The company has a debt-to-equity ratio of 0.79, a current ratio of 0.79 and a quick ratio of 0.61. Hologic, Inc. has a one year low of $35.76 and a one year high of $46.80. The company has a market cap of $11,548.39, a PE ratio of 20.74, a P/E/G ratio of 2.03 and a beta of 0.95.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Wednesday, November 8th. The medical equipment provider reported $0.50 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.49 by $0.01. Hologic had a net margin of 24.70% and a return on equity of 21.69%. The business had revenue of $802.90 million for the quarter, compared to the consensus estimate of $792.54 million. During the same period in the prior year, the company posted $0.52 earnings per share. Hologic’s revenue was up 10.5% compared to the same quarter last year. research analysts anticipate that Hologic, Inc. will post 2.12 EPS for the current fiscal year.

HOLX has been the topic of several research reports. Needham & Company LLC reiterated a “buy” rating and issued a $50.00 price objective on shares of Hologic in a report on Monday, October 2nd. Piper Jaffray Companies reiterated a “buy” rating and issued a $48.00 price objective on shares of Hologic in a report on Thursday, November 9th. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $45.00 price objective (down from $50.00) on shares of Hologic in a report on Wednesday, August 9th. Barclays reiterated an “equal weight” rating and issued a $51.00 price objective (down from $53.00) on shares of Hologic in a report on Wednesday, August 9th. Finally, Jefferies Group reiterated a “buy” rating and issued a $44.00 price objective (down from $49.00) on shares of Hologic in a report on Tuesday, October 10th. One analyst has rated the stock with a sell rating, five have issued a hold rating and nine have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $47.38.

TRADEMARK VIOLATION NOTICE: “Hologic, Inc. (HOLX) Position Trimmed by American International Group Inc.” was first posted by Stock Observer and is owned by of Stock Observer. If you are reading this report on another site, it was stolen and reposted in violation of US & international copyright law. The legal version of this report can be accessed at https://www.thestockobserver.com/2017/12/07/hologic-inc-holx-position-trimmed-by-american-international-group-inc.html.

Hologic Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply